Associated tags: Patient, Stock exchange, Motherboard, CMS, Hospital, Safety, Pharmaceutical industry, Incidence, Tablet
Locations: SHENZHEN, CHINA, CN, HONG KONG, TAIWAN, MACAU, JAPAN, UNITED STATES
CMS,
Tablet,
Desidustat,
NMPA,
NDA,
National Medical Products Administration,
Kidney failure,
New Drug Application,
Erythropoiesis,
Anemia,
Chronic kidney disease,
CKD,
Week,
Patient,
Dialysis,
Prevalence,
Marketing,
Diagnosis,
Advertising,
EPO,
Medical device Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.
Key Points:
- Desidustat Tablets are novel, oral HIF-PHI for treating anaemia in non-dialysis adult chronic kidney disease patients.
- The primary endpoint has indicated that Desidustat is more effective than placebo in increasing Hb level.
- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 April 2024, the New Drug Application (NDA) of Desidustat Tablets (“Desidustat Tablets” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA).
- Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
Dermatology,
Vitiligo,
Prurigo nodularis,
Patient,
Collaboration,
Research,
Asthma,
JAK1,
HS,
Hidradenitis suppurativa,
PN,
CMS,
Autoimmunity,
Pharmaceutical industry Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
Key Points:
- Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.
- CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
- “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Herve Hoppenot, Chief Executive Officer, Incyte.
- Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline ILUMETRI (tildrakizumab injection), original drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.”
The transaction is effective immediately upon the execution of the Collaboration and License Agreement.
Sclerotherapy,
RMB,
Conditional sentence,
NDA,
IND,
Creativity,
Small RNA,
Marketing,
Gastroenterology,
Central nervous system,
FIC,
City,
BIC,
CMS,
NRDL,
Injection,
Dermatology,
CDMO,
Commercialization,
Tablet,
Pharmacy,
Methotrexate,
Hospital,
Acquisition,
Gonadotropin-releasing hormone,
RCT,
VBP,
Rheumatoid arthritis,
Growth,
Varicose veins,
Ecosystem,
Blue,
Government,
Ophthalmology SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.
Key Points:
- SHENZHEN, CHINA, March 27, 2024 (GLOBE NEWSWIRE) -- On March 27, 2024, China Medical System (“CMS” or the “Company”) released its 2023 annual results.
- Based on above, CMS has successfully entered into its “New Period” of innovation and internationalization development.
- 4 innovative drugs have started large-scale clinical application, unveiling CMS’s first year of commercialization era of innovative drugs.
- Under its compliant and efficient commercialization system, the Company's innovative products and exclusive drugs will grow steadily.
SP,
License,
Peritoneal dialysis,
Patient,
National Medical Products Administration,
Ageing,
Glomerular filtration rate,
CKD,
NMPA,
HD,
Dialysis,
CMS,
Sale,
Chronic kidney disease,
PB,
PD,
Pharmaceutical industry Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023.
Key Points:
- Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023.
- Upon the expiration of the aforementioned term, the License Agreement may automatically be renewed for ten years as per certain conditions defined in the License Agreement.
- There is an issued patent that protects the formulation, usage, particle size and manufacturing methods of the Product in China.
- Velphoro® is a newly approved innovative drug in China in 2023 and has been successfully included in category B of the National Reimbursement Drug List.
Marketing,
Policy,
Ecosystem,
Drug development,
HSA,
FDA,
Acquisition,
CDMO,
PTE,
Outline of health sciences,
Patient,
Therapeutic Goods Administration,
Safety,
International (Amtrak train),
Food and Drug Administration,
TGA,
CMS,
Fine chemical Ltd. ( defined as “Singapore manufacturing plant ”).
Key Points:
- Ltd. ( defined as “Singapore manufacturing plant ”).
- The Singapore manufacturing plant has advanced manufacturing machines, equipment and first-class infrastructure.
- It will serve as the plant and site for PharmaGend to carry out pharmaceutical formulation, finishing, and packaging business, accelerating the formulation Contract Development and Manufacturing Organization (formulation CDMO) business development in Singapore.
- The smooth progress of the formulation CDMO cooperation is of great significance to CMS in accelerating its business development in Southeast Asia.
Retrieved on:
Wednesday, December 13, 2023
Marketing,
Shanghai Stock Exchange,
Quality of life,
Epilepsy,
A&B,
Peptide,
Absorption,
National Healthcare,
Methotrexate,
National Healthcare Security Administration,
Insurance,
Safety,
Tetrabenazine,
Heart failure,
CMS,
Protein,
Light,
Recombinant,
Acute decompensated heart failure,
Sun Pharma,
Nasal mucosa,
PASI,
Tablet,
Patient,
Psoriasis,
Chemokine,
Diazepam,
Huntington's disease,
Sale,
Social Security,
Tildrakizumab,
Social,
Vitamin E China Medical System actively responds to national policies to promote innovative products to be included in the NRDL.
Key Points:
- China Medical System actively responds to national policies to promote innovative products to be included in the NRDL.
- In addition, innovative drug Methotrexate Injection (Metoject) indicated for psoriasis approved in March 2023 has been included in category A of the National Reimbursement Drug List.
- It is the first nasal spray formulation of diazepam in China and the first drug approved in China for the treatment of seizure clusters.
- CMS actively responds to national policies to promote innovative products to be included in the National Reimbursement Drug List.
Marketing,
Light,
PUVA,
MTX,
European,
Methotrexate,
Blue,
NDA,
Rheumatoid arthritis,
Tablet,
New Drug Application,
NMPA,
Study,
Gemeinschaft and Gesellschaft,
Retinoid,
National Medical Products Administration,
Patient,
Safety,
Psoriasis,
Injection,
Communication,
Pharmaceutical industry The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection.
Key Points:
- The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection.
- The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China.
- China Medical System Holdings Limited ( “CMS” or the “Group”) announced that on 4 December 2023, the New Drug Application (NDA) for an additional indication of its innovative product, Methotrexate Injection (the “Product”), has been accepted by the National Medical Products Administration of China (NMPA).
- The Product is a small-volume methotrexate injection with various strengths, which is intended to be used to treat active rheumatoid arthritis (RA) in adult patients.
Retrieved on:
Thursday, August 24, 2023
Agreement,
Post-stroke depression,
CMS,
Central nervous system,
Marketing,
Stroke,
Y-3,
NOS1,
DSM-IV codes,
Tablet,
Incidence,
Patient,
Health,
Phase,
Family,
Safety,
Pharmaceutical industry Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke.
Key Points:
- Y-3, a Class 1 Innovative Drug injection, is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke.
- After approved for marketing in China, it is expected to meet the clinical needs of drug with both safety and efficacy, providing new treatment options to ischemic stroke patients in China.
- Y-3 Injection is a Class 1 innovative drug - small molecule compound, which is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke.
- For further detailed information, please visit the following link for the announcement , “Voluntary and Business Update Announcement Gaining Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug” issued by CMS on August 24 2023.
SHENZHEN, CHINA, July 31, 2023 (GLOBE NEWSWIRE) -- Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited (“CMS” or the “Group”), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
Key Points:
- SHENZHEN, CHINA, July 31, 2023 (GLOBE NEWSWIRE) -- Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited (“CMS” or the “Group”), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
- MSCI is one of the most widely used, influential, and referenced rating companies in the global market.
- MSCI-ESG rating results have been regarded by global investors as an important non-financial basis for investment decision-making.
- Being back to the "AA" rating, reflects the full recognition of the Group's ESG management practices by the international authoritative rating company.
S&P Global,
CMS,
United Nations,
Marketing,
Sustainable Development Goals,
Yearbook,
Attention,
Sustainable development,
Patient,
ESG,
Environment,
Dimension stone CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global.
Key Points:
- CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global.
- Recently, S&P Global, the world's leading corporate sustainability assessment institution, has officially released the first "Sustainability Yearbook 2023 (China)".
- China Medical System Holdings Limited (“CMS” or the “Group”), standing out from many outstanding companies, was successfully included in this Yearbook.
- S&P Global has published global versions of the “Sustainability Yearbook” for 16 consecutive years, and has received extensive attention and recognition.
